The long-standing war against cancer has been a battle of attrition, often fought at a terrible cost to the patient. While treatments like…

Human papillomavirus (HPV) causes around 70% of head and neck cancers in the United States, making it the most common cancer caused by the virus, with rates increasing each year. Unlike cervical cance...

Scientists have found a way to supercharge lung cancer treatment by transplanting healthy mitochondria into tumors, which both boosts immune response and makes chemotherapy far more effective. By comb...

The one-time infusion for multiple myeloma is being billed as a functional cure by cancer doctors.

Van Andel Institute scientists and collaborators have discovered a potential treatment target that may re-energize dysfunctional or "exhausted" immune cells in their fight against cancer.

Could electricity be the missing key in the fight against brain cancer? A groundbreaking new therapy combining electric fields, chemo and immunotherapy shows a dramatic 70% increase in survival for glioblastoma patients.

Stanford scientists have developed a molecule that forces cancer cells to self-destruct—by hijacking their survival systems from the inside. Early lab tests show it kills even drug-resistant tumors, m...

A smart nanoparticle from OHSU delivers drugs and ultrasound energy to tumors—shattering cancer cells with less risk and more precision.

Explore how mRNA vaccines, from COVID-19 to cancer, are revolutionizing treatments and empowering your immune system in this game-changing article!

A new study announces exciting results for certain solid tumors. Is Jemperli a cancer breakthrough? If the cancers are "dMMR," quite possibly!

Up to 15,000 could be given nivolumab in injectable form to treat 15 cancers including lung, bowel and skin cancer

Patients with some gastrointestinal tumors were able to be treated with immunotherapy drugs alone and avoid surgery, chemotherapy or radiation, the study found.

Although cytotoxic CD8+ T lymphocytes (CTLs) are essential for anti-tumour immunity, they are frequently dysfunctional in tumours1. Cytokines that sustain CTL activity are attractive for cancer immunotherapy, but avoiding inflammatory toxicity remains a challenge for their clinical use2. Here we show that expression of a CTL signature is strongly associated with IL27 expression in human and mouse tumours. In mice, IL-27 acts directly on tumour-specific CTLs to promote their persistence and effector function in the tumour microenvironment. Moreover, treatment with inducible IL-27 overexpression or a half-life-extended IL-27 protein in vivo is well tolerated, induces regression of established tumours, drives an enhanced cytotoxic program in anti-tumour CTLs and synergizes with PD-L1 blockade. In patients with cancer who were treated with anti-PD-1/PD-L1 therapy, high expression of IL-27 correlates with a favourable clinical response, and IL-27 supports human CTL function during chronic a

Cancer genome alterations often lead to vulnerabilities that can be used to selectively target cancer cells. Various inhibitors of such synthetic lethal targets have been approved by the FDA or are in clinical trials, highlighting the potential of this approach1–3. Here we analysed large-scale CRISPR knockout screening data from the Cancer Dependency Map and identified a new synthetic lethal target, PELO, for two independent molecular subtypes of cancer: biallelic deletion of chromosomal region 9p21.3 or microsatellite instability-high (MSI-H). In 9p21.3-deleted cancers, PELO dependency emerges from biallelic deletion of the 9p21.3 gene FOCAD, a stabilizer of the superkiller complex (SKIc). In MSI-H cancers, PELO is required owing to MSI-H-associated mutations in TTC37 (also known as SKIC3), a critical component of the SKIc. We show that both cancer subtypes converge to destabilize the SKIc, which extracts mRNA from stalled ribosomes. In SKIc-deficient cells, PELO depletion i

Findings could help doctors predict and slow brain tumor regrowth, leading to more personalized treatments for glioblastoma

Northwestern researchers discovered a hidden metabolic role for Menin in leukemia—offering a powerful new target for more effective, personalized treatments.

Synthetic lethality exploits the genetic vulnerabilities of cancer cells to enable a targeted, precision approach to treat cancer1. Over the past 15 years, synthetic lethal cancer target discovery approaches have led to clinical successes of PARP inhibitors2 and ushered several next-generation therapeutic targets such as WRN3, USP14, PKMYT15, POLQ6 and PRMT57 into the clinic. Here we identify, in human cancer, a novel synthetic lethal interaction between the PELO–HBS1L and SKI complexes of the mRNA quality control pathway. In distinct genetic contexts, including 9p21.3-deleted and high microsatellite instability (MSI-H) tumours, we found that phenotypically destabilized SKI complex leads to dependence on the PELO–HBS1L ribosomal rescue complex. PELO–HBS1L and SKI complex synthetic lethality alters the normal cell cycle and drives the unfolded protein response through the activation of IRE1, as well as robust tumour growth inhibition. Our results indicate that PELO and HB